Breaking News Instant updates and real-time market news.

CRWD

Crowdstrike

$72.75

1.77 (2.49%)

, SKX

Skechers

$34.75

0.35 (1.02%)

18:50
07/18/19
07/18
18:50
07/18/19
18:50

Fly Intel: After Hours Movers

UP AFTER EARNINGS: CrowdStrike (CRWD) up 13.8%... Skechers (SKX) up 11.4%... Exponent (EXPO) up 4.7%... Microsoft (MSFT) up 2.5%... Chewy (CHWY) up 2.1%. ALSO HIGHER: Red Robin (RRGB) up 16.1% after Vintage Capital disclosed offer to purchase company at $40 per share... Gannett (GCI) up 11.8% after WSJ speculation the company is in late-stage merger talks with GateHouse Media... InflaRX (IFRX) up 8.9% after disclosing "robust anti-inflammatory activity" in Phase 2b study of IFX-1... Boeing (BA) up 2.3% after announcing $4.9B charge related to 737Max grounding. DOWN AFTER EARNINGS: MicroVision (MVIS) down 12.8%... Bank OZK (OZK) down 2.9%... Intuitive Surgical (ISRG) down 1.6%. ALSO LOWER: Alcoa (AA) down 1.1% after being downgraded to Hold at Jefferies. Movers as of 18:30ET.

CRWD

Crowdstrike

$72.75

1.77 (2.49%)

SKX

Skechers

$34.75

0.35 (1.02%)

EXPO

Exponent

$61.63

0.83 (1.37%)

MSFT

Microsoft

$136.29

0.06 (0.04%)

CHWY

Chewy

$32.79

1.14 (3.60%)

RRGB

Red Robin

$30.58

0.32 (1.06%)

GCI

Gannett

$7.90

-0.185 (-2.29%)

IFRX

InflaRx

$3.12

0.05 (1.63%)

BA

Boeing

$361.17

-8.28 (-2.24%)

MVIS

MicroVision

$0.86

0.0458 (5.62%)

OZK

Bank OZK

$28.61

0.5 (1.78%)

ISRG

Intuitive Surgical

$536.44

13.25 (2.53%)

AA

Alcoa

$23.42

0.27 (1.17%)

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 19

    Jul

  • 23

    Jul

  • 24

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 26

    Aug

  • 26

    Aug

  • 09

    Sep

  • 23

    Sep

  • 16

    Oct

CRWD Crowdstrike
$72.75

1.77 (2.49%)

07/08/19
07/08/19
INITIATION
Target $90

Outperform
Crowdstrike initiated with an Outperform at Oppenheimer
Oppenheimer analyst Shaul Eyal started coverage of Crowdstrike with an Outperform rating and $90 price target. The analyst cited the company's innovative technology, his belief Crowdstrike will continue to disrupt and gain market share from legacy and next generation antivirus vendors, industry's shift to consolidate point product solutions and shortage of cyber-skilled talents should drive customers to seek a holistic solution like Crowdstrike's, large and expanding TAM estimated to exceed $30B by 2022, and hypergrowth rate over 30% expected over the next several years.
07/08/19
07/08/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Best Buy (BBY) initiated with a Buy at Guggenheim. 2. Cabot Microelectronics (CCMP) was initiated with a Buy at Goldman Sachs and a Neutral at CL King. 3. Crowdstrike (CRWD) was initiated with an Outperform at Oppenheimer, Macquarie and JMP Securities, an Overweight at JPMorgan, Piper Jaffray and Barclays, a Buy at BofA/Merrill, Needham, Stifel, and Mizuho, a Neutral at Credit Suisse and Goldman Sachs, a Sector Perform at RBC Capital, and a Hold at SunTrust and Jefferies. 4. TriplePoint Venture (TPVG) initiated with a Buy at Nomura Instinet. 5. Fiverr (FVRR) was initiated with an Outperform at Oppenheimer and JMP Securities, a Buy at Needham, as well as a Neutral at JPMorgan, UBS and Citi. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/08/19
RHCO
07/08/19
INITIATION
Target $69
RHCO
Hold
Crowdstrike initiated with a Hold at SunTrust
SunTrust analyst Terry Tillman initiated Crowdstrike with a Hold rating and a price target of $69. The analyst says that he is positive on the company's market-share winning cloud security platform that offers "unmatched protection against cyber attacks and stopping breaches" amid the broader investment themes of security workloads moving to the cloud as well as the proliferation of AI and big data "intensifying" the threat landscape. Tillman contends however that Crowdstrike's triple-digit revenue growth and margin expansion are likely reflected in its 25-times enterprise value to expected FY20 sales multiple.
07/08/19
FBCO
07/08/19
INITIATION
Target $70
FBCO
Neutral
Crowdstrike initiated with a Neutral at Credit Suisse
Credit Suisse analyst Brad Zelnick started coverage of Crowdstrike with a Neutral rating and $70 price target. The analyst appreciates CrowdStrike's success in disrupting the established, yet rapidly evolving, market for endpoint security but are cautious of valuation and competition.
SKX Skechers
$34.75

0.35 (1.02%)

07/11/19
OTRG
07/11/19
UPGRADE
OTRG
Positive
Skechers upgraded to Positive from Mixed at OTR Global
05/14/19
COWN
05/14/19
NO CHANGE
COWN
Skechers, G-III among apparel names with outsized tariff risk, says Cowen
Cowen analyst John Kernan said 34% of apparel and about 70% of footwear imported into the U.S. come from China, adding that 25% tariffs on apparel and footwear will create "major disruption" at a time when companies are already facing accelerating disruption from technology and Amazon (AMZN). The analyst, who thinks diversifying from China sourcing will be slow, said he views Skechers (SKX), G-III Apparel (GIII), Carter's (CRI), PVH Corp. (PVH) and Ralph Lauren (RL) as among the apparel stocks with outsized EPS risk. He added that he thinks companies like Under Armour (UAA), that may have lower than sector average exposure to China sourcing but also have lower EBIT margins, as faced with greater sensitivity to higher cost of goods.
03/27/19
SUSQ
03/27/19
UPGRADE
SUSQ
Positive
Skechers upgraded to Positive from Neutral at Susquehanna
03/27/19
SUSQ
03/27/19
UPGRADE
Target $37
SUSQ
Positive
Skechers upgraded to Positive on signs of increased momentum at Susquehanna
Susquehanna analyst Sam Poser upgraded Skechers to Positive from Neutral, stating that his checks with family footwear and independent retailers and recent results from wholesalers point to increased momentum for its brands. Given the signs he sees that its business is at the beginning of a positive inflection, Poser said he is confident that Skechers' operating margin is "on the road" back to its prior peak level of 11.5%. He raised his price target on Skechers shares to $37 from $32.
EXPO Exponent
$61.63

0.83 (1.37%)

04/22/19
CANT
04/22/19
NO CHANGE
Target $64
CANT
Overweight
Exponent price target raised to $64 from $56 at Cantor Fitzgerald
Cantor Fitzgerald analyst Joseph Foresi raised his price target for Exponent to $64 from $56 and maintains an Overweight rating on the shares following the company's Q1 results. The nature of the company's business gives Exponent an advantage in its ability to deliver results regardless of the economic backdrop, Foresi tells investors in a research note. He expects its revenue to grow in the mid-to high-single-digit range for all of 2019, with the opportunity for upside to "conservative" guidance.
09/12/18
BREN
09/12/18
INITIATION
Target $63
BREN
Buy
Exponent initiated with a Buy at Berenberg
Berenberg started Exponent with a Buy rating and $63 price target.
07/20/18
RHCO
07/20/18
NO CHANGE
Target $56
RHCO
Buy
Exponent price target raised to $56 from $47.50 at SunTrust
SunTrust analyst Tobey Sommer raised his price target on Exponent to $56 after its Q2 earnings beat along with its raised EBITDA margin guidance. Sommer says the "industry-focused sale teams" are driving market share gains in the "lucrative large proactive engagements", while the company's new CEO Catherine Corrigan also offered "crisp" and "insightful" answers on the earnings call. The analyst is keeping his Buy rating on Exponent, stating the company's underlying growth remains firm, while its focus on "cross-selling by forming industry-focused sales teams" should also allow it to capture market share.
MSFT Microsoft
$136.29

0.06 (0.04%)

07/18/19
OPCO
07/18/19
NO CHANGE
Target $145
OPCO
Outperform
Oppenheimer expects 'strong quarter' from Microsoft driven by cloud
Oppenheimer analyst Timothy Horan expects a "strong quarter" from Microsoft as it is seeing momentum in its cloud-based business, which now represents a third of revenues and is growing 35% year over year. The analyst notes that Microsoft has habitually posted beat-and-raise quarters, with the last results to miss guidance more than two years ago and expects a similar beat this quarter. Horan reiterates an Outperform rating and $145 price target on the shares.
07/17/19
FBCO
07/17/19
NO CHANGE
Target $145
FBCO
Outperform
Credit Suisse expects Microsoft to report 'solid' Q4 results
Credit Suisse analyst Brad Zelnick expects Microsoft to report "solid" Q4 results, as the company continues to execute against its vast opportunity set, spanning the Intelligent Cloud to the Intelligent Edge. While the analyst remains mindful of the increasingly difficult compares the company faces through the remainder of the calendar year, he expects management will provide 2020 guidance in line with its preliminary view of double-digit revenue and operating income growth. Zelnick reiterates an Outperform rating and $145 price target on the shares.
07/17/19
SBSH
07/17/19
INITIATION
Target $39
SBSH
Neutral
Slack Technologies initiated with a Neutral at Citi
Citi analyst Walter Pritchard started Slack Technologies (WORK) with a Neutral rating and $39 price target. Both Microsoft (MSFT) and Alphabet (GOOGL) see the productivity and collaboration software category as a strategic imperative and are investing, which will keep competitive pressure on Slack, Pritchard tells investors in a research note.
07/16/19
WEDB
07/16/19
NO CHANGE
Target $155
WEDB
Outperform
Wedbush expects another 'strong' performance from Microsoft on cloud success
Ahead of Microsoft's quarterly results, Wedbush analyst Daniel Ives expects the company to post a "solid beat" across the board on both the top and bottom line as cloud strength on Azure and Office 365 continues to be the fuel in the tank with strong field checks indicating the company could beat commercial cloud expectations by about 3%-plus. The analyst believes the shift to cloud is a major secular trend and key tailwind that is significantly benefiting Microsoft in the field and should continue its momentum heading into fiscal year 2020 based on his checks showing an inflection point of demand is abound. Ives reiterates an Outperform rating and $155 price target on the shares.
CHWY Chewy
$32.79

1.14 (3.60%)

07/09/19
WBLR
07/09/19
INITIATION
WBLR
Outperform
Chewy initiated with an Outperform at William Blair
William Blair analyst Dylan Carden initiated coverage of Chewy with an Outperform rating. At $34, the shares trade at 2.3 times estimated 2020 sales, a relative discount to other online retail platforms and subscription models, which trade closer to four times 2020 sales, Carden tells investors in a research note. The analyst sees room for multiple expansion but believes the "greatest value" for shareholders stems from the company's opportunity to continue to capture disproportionate market share of a "healthy and fast-growing" industry.
07/09/19
RAJA
07/09/19
INITIATION
RAJA
Market Perform
Chewy shares fairly valued, risk-reward balanced, says Raymond James
Raymond James analyst Aaron Kessler initiated Chewy with a Market Perform rating. In a research note to investors, Kessler says he believes shares have several positive fundamental attributes, including a large pet care market that is shifting online, "predictable" customer economics, the expectation for about 20% long-term growth and 5%-10% long-term EBITDA margin expansion. At the same time, Kessler says he believes shares are currently fairly valued and that risk-reward is more balanced at current levels.
07/15/19
CHLM
07/15/19
NO CHANGE
CHLM
Sell
PetMed CEO amendment hints at exploration of alternatives, says Craig-Hallum
Craig-Hallum analyst Kevin Ellich noted that PetMed Express (PETS) filed an 8K after the close on Friday to disclose that it amended CEO Mendo Akdag's employment agreement to add the language "for Good Reason" to the "Change in Control" section. He reads this change as a hint that an exploration of strategic alternatives could be upcoming, though he doesn't think there is anything imminent in the works. The analyst, who suspects there is further downside to Street estimates for PetMed given increased competition from Chewy (CHWY), Walmart (WMT), Petco and other online retailers, keeps a Sell rating on PetMed shares.
07/09/19
07/09/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Chewy (CHWY) was initiated with an Outperform at William Blair and Wells Fargo, an Overweight at JPMorgan, a Buy at BofA/Merrill and UBS, an Equal Weight at Morgan Stanley and Barclays, a Market Perform at Raymond James, a Sector Perform at RBC Capital, a Hold at Jefferies, and a Neutral at Nomura Instinet. 2. Intellia Therapeutics (NTLA) initiated with an Outperform at Baird. 3. Slack Technologies (WORK) initiated with a Perform at Oppenheimer. 4. AAR Corp. (AIR) initiated with a Buy at Stifel. 5. Vista Outdoor (VSTO) initiated with a Buy at Lake Street. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
RRGB Red Robin
$30.58

0.32 (1.06%)

06/13/19
SPHN
06/13/19
NO CHANGE
Target $36
SPHN
Overweight
Red Robin 'interesting' for prospective private equity buyers, says Stephens
Stephens analyst Will Slabaugh notes that Vintage Capital filed a 13-D stating its belief that the Board of Red Robin should "immediately commence a comprehensive review of strategic alternatives, including an auction of the Issuer", with Vintage prepared to call a special meeting of shareholders to potentially remove members of the Board if they do not promptly commit to reviewing possible strategic-alternatives. While Red Robin has shown "poor business momentum" recently, the analyst points out that the company's substantial cash-flow profile, refranchising potential, and attractive valuation make the company "interesting" for prospective Private Equity buyers. Vintage Capital now holds an 11.6% stake and stated they "are prepared to bid $40 per-share in the auction process to acquire 100% of the company in an all-cash transaction," Slabaugh adds. The analyst has an Overweight rating and $36 price target on the shares.
06/14/19
MAXM
06/14/19
UPGRADE
Target $49
MAXM
Buy
Red Robin upgraded to Buy from Hold at Maxim
Maxim analyst Stephen Anderson upgraded Red Robin to Buy from Hold and raised his price target on the shares to $49, citing his view that a takeover is increasingly likely following the letter sent to the board by investor Vintage Capital.
05/16/19
MAXM
05/16/19
NO CHANGE
Target $32
MAXM
Hold
Red Robin price target raised to $32 from $25 at Maxim
Maxim analyst Stephen Anderson raised his price target on Red Robin to $32 ahead of its Q1 results on May 30th. The analyst says his new price target accounts for the possibility of an activist-driven takeover after last week's announcement by Vintage Capital Management taking an 8.5% stake in the company. Anderson also keeps his Hold rating on Red Robin shares.
04/05/19
MAXM
04/05/19
NO CHANGE
Target $25
MAXM
Hold
Red Robin price target lowered to $25 from $29 at Maxim
Maxim analyst Stephen Anderson lowered his price target on Red Robin to $25 and kept his Hold rating after its CEO transition announcement and a bigger than expected Q1 comps decline outlook. The analyst believes that the CEO exit reduces the visibility for the company's turnaround, also lowering his Q1 EPS forecast to 42c from 56c and FY19 view to $1.23 from $1.42 on the disappointing comps guidance.
GCI Gannett
$7.90

-0.185 (-2.29%)

IFRX InflaRx
$3.12

0.05 (1.63%)

06/05/19
RAJA
06/05/19
DOWNGRADE
RAJA
Market Perform
InflaRx downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Steven Seedhouse downgraded InflaRx to Market Perform from Outperform after the company's Phase IIb study in hidradenitis suppurativa failed to meet its endpoint. At least seven other firms have also downgraded InflaRx today following the company's report of data from its SHINE Phase IIb study.
06/06/19
RAJA
06/06/19
NO CHANGE
Target $17
RAJA
Strong Buy
ChemoCentryx price target lowered to $17 from $24 at Raymond James
Raymond James analyst Steven Seedhouse removed hidradenitis suppurativa from his model for ChemoCentryx (CCXI) after InflaRx (IFRX) reported that its Phase IIb trial for C5a antibody IFX-1 failed, leading him to lower his price target on the shares to $17 from $24. However, he keeps a Strong Buy rating on ChemoCentryx shares and said he would be a buyer amid the weakness, citing Phase 2 data for avacopan in AAV and a near-term Phase 3 data readout for AAV in Q4.
06/05/19
PIPR
06/05/19
NO CHANGE
Target $17
PIPR
Overweight
Piper Jaffray cuts ChemoCentryx target to $17 after InflaRx failure
Piper Jaffray analyst Edward Tenthoff lowered his price target for ChemoCentryx (CCRX) to $17 from $20 after its competitor InflaRx (IFRX) reported negative Phase IIb data for C5a antibody IFX-1 to treat moderate-to-severe hidradenitis suppurativa. ChemoCentryx shares are down because the company has its own small molecule avacopan targeting C5a receptor in an ongoing Phase II hidradenitis suppurativa study with data in 2020, Tenthoff tells investors in a research note. The analyst says that while nuances exist between InflaRx's IFX-1 and ChemoCentryx's avocopan for receptor coverage and distribution, the lack of dose response in InflaRx's Phase II data raises concern over the relevancy of C5a in hidradenitis suppurativa. As a result, Tenthoff removed value for avacopan in hidradenitis suppurativa in his model but remains a buyer of ChemoCentryx shares for the Phase III Advocate avacopan data in ANCA-associated vasculitis in Q4 of this year. He keeps an Overweight rating on the shares, which are down 17% to $9.18 in afternoon trading.
06/05/19
06/05/19
DOWNGRADE

Market Perform
InflaRx downgraded to Market Perform on HS study results at Raymond James
As previously reported, Raymond James analyst Steven Seedhouse downgraded InflaRx (IFRX) to Market Perform from Outperform as it is now trading below cash and thereby baking in what he believes is an appropriate value, which is zero value for hidradenitis suppurativa and risk to all follow-on indications in the pipeline for IFX-1. The analyst acknowledges that HS may not be a viable indication for C5a pathway inhibition, which seems "quite clear from InflaRx's failed study." Seedhouse adds that there is "obvious negative read-through" to Chemocyntrx (CCXI), which is running a large Phase 2 randomized study in HS for avacopan. He expects that study to at a minimum fail or maybe even be stopped early given the complete lack of signal demonstrated by IFX-1.
BA Boeing
$361.17

-8.28 (-2.24%)

07/18/19
07/18/19
DOWNGRADE

Neutral
Allegheny Technologies cut to Neutral at Longbow on reduced aerospace visibility
As previously reported, Longbow analyst Christopher Olin downgraded Allegheny Technologies (ATI) to Neutral from Buy, citing "too many negative survey points" to remain positive on the visibility for the company commercial aerospace demand. The analyst warns that a potential rate cut assessment that may be issued by Boeing (BA) or General Electric (GE) when they announce results could weigh on investor sentiment for Allegheny Technologies in the second half of 2019 and believes that the FY20 earnings guidance for the entire specialty materials group could come under pressure.
07/08/19
COWN
07/08/19
NO CHANGE
COWN
Outperform
Boeing MAX recertification pushout to increase cash flow volatility, says Cowen
Cowen analyst Cai von Rumohr commented on the potential impact of the expected pushout of recertification of Boeing's (BA) MAX aircraft to late September, saying he thinks the extended timeline will increase cash flow volatility for Boeing and risk of 737 rate cut at Spirit AeroSystems (SPR) and GE (GE). The analyst tells investors in a research note that he now sees an 737 inventory cash outflow in Q2 of $3.5B-$4B with a total Q2 outflow of $1B-$2B and more in Q3, and says Boeing will overall have about 275 completed MAXes in inventory at the end of Q3, which will take time to work through since the priority is to get the 381 MAXes already sitting in fleets back into service. Selling for an 8.5% "normalized" cash flow yield, Von Rumohr says Boeing remains his top pick.
07/08/19
FBCO
07/08/19
DOWNGRADE
Target $30
FBCO
Underperform
American Airlines downgraded to Underperform from Neutral at Credit Suisse
Credit Suisse analyst Jose Caiado downgraded American Airlines (AAL) to Underperform from Neutral on labor and Boeing (BA) 737 Max risk. While these issues may be transient, they add to an already-challenged 2019 cost outlook and "unfortunately mask" some of the progress that American Airlines is making on the commercial front this year, he contends. The analyst also lowered his price target on American's shares to $30 from $32.
07/18/19
07/18/19
DOWNGRADE

Neutral
Arconic cut to Neutral at Longbow on 737Max exposure
As previously reported, Longbow analyst Christopher Olin downgraded Arconic (ARNC) to Neutral from Buy going into the Q2 updates by aerospace OEM companies. As a "key supplier" of premium forged products, aero fasteners, and specialty materials, the analyst contends that the company is too exposed to the reduced expectations around Boeing's (BA) 737Max and/or LEAP engine programs.
MVIS MicroVision
$0.86

0.0458 (5.62%)

12/19/18
CHLM
12/19/18
INITIATION
Target $1.75
CHLM
Buy
MicroVision initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Mike Malouf started MicroVision with a Buy rating and $1.75 price target. The analyst's optimistic case scenario assumes the smart Smart Speaker market grows to 100M units over the next few years, with 6.5M units incorporating the company's display-only capability and 3M integrating its interactive display functionality. Including other verticals, Malouf believes the company could generate $300M in revenue and over $50M in EBITDA, which at 8 times results in a $3.50 stock, or a 500% return.
OZK Bank OZK
$28.61

0.5 (1.78%)

01/22/19
RHCO
01/22/19
NO CHANGE
Target $35
RHCO
Hold
Bank OZK price target raised to $35 from $25 at SunTrust
SunTrust analyst Jennifer Demba raised her price target on Bank OZK to $35 after its Q4 earnings and preliminary FY19 guidance. The analyst cites the company's net interest margin expansion given the easing in deposit pricing, along with the management's greater focus on deposit gathering and pricing analytics. Demba also notes the subsiding asset quality fears for the bank, with commercial real estate loan project sales velocity and pricing holding up and net charge offs coming in "more normal" in the quarter. The analyst keeps her Hold rating on the shares after their 40% run-up year to date.
01/22/19
BMUR
01/22/19
NO CHANGE
Target $38
BMUR
Buy
Bank OZK discount provides upside opportunity, says Brean Capital
Brean Capital analyst Blair Brantley noted Bank OZK reported solid Q4 results highlighted by NIM expansion, favorable net loan growth, fee income expansion, and more typical credit related results. He raised his estimates but said it remains a "show-me" story for the next few quarters. Brantley believes upside exists as additional quarters like Q4 are achieved. Brantley reiterated his Buy rating and $38 price target on Bank OZK shares.
01/10/19
LEHM
01/10/19
NO CHANGE
LEHM
Barclays upgrades Mid-Cap Banks industry to Positive from Neutral
Barclays analyst Matthew Keating upgraded his view on the U.S. Mid-Cap Banks industry to Positive from Neutral. There seems to be a lot less enthusiasm for the banks this year, Keating tells investors in a research note. The focus this year is on rising trade tensions, slowing global growth, and chance of a recession, says the analyst. However, he believes the slide in bank stock sentiment creates opportunities for investors "willing to withstand some volatility in the near term." Along with the sector, Keating upgraded Synovus Financial (SNV) and Texas Capital (TCBI) to Overweight from Equal Weight and Bank OZK (OZK) and People's United Financial (PBCT) to Equal Weight from Underweight. Based on his relative ratings system, he downgraded Prosperity Bancshares (PB) to Equal Weight from Overweight and New York Community Bancorp (NYCB) to Underweight from Equal Weight.
01/22/19
LEHM
01/22/19
NO CHANGE
Target $36
LEHM
Overweight
Bank OZK price target raised to $36 from $28 at Barclays
In a post-earnings research note titled "What a Difference a Year Can Make," Barclays analyst Matthew Keating raised his price target for Bank OZK to $36 from $28 and keeps an Overweight rating on the shares. OZK's preliminary 2019 outlook calls for low-to-mid-teens non-purchased loan growth, moderation in its cost of interest bearing deposits, and continued "excellent" asset-quality trends, Keating writes. He thinks the company drives high-single-digit loan and earnings growth this year.
ISRG Intuitive Surgical
$536.44

13.25 (2.53%)

04/23/19
SBSH
04/23/19
NO CHANGE
Target $611
SBSH
Buy
Intuitive Surgical price target lowered to $611 from $684 at Citi
Citi analyst Amit Hazan lowered his price target for Intuitive Surgical to $611 from $684 following last week's "surprise miss" but keeps a Buy rating on the shares. The analyst sees "very solid leading indicators that offer encouragement for longer term fundamentals." He also believes the recent weakness in the shares present a "compelling buying opportunity."
05/22/19
PIPR
05/22/19
NO CHANGE
Target $610
PIPR
Overweight
Intuitive Surgical has opportunity to upgrade install base, says Piper Jaffray
Following an analysis of the da Vinci Surgeon Locator tool, Piper Jaffray analyst JP McKim says that while Intuitive Surgical has at least one robot in the majority of large hospitals, the company has a "real opportunity to go deeper and upgrade the install base." Further, there is room in the market for a lower cost, smaller footprint offering to attract small hospitals, McKim tells investors in a research note. The analyst keeps an Overweight rating on Intuitive Surgical shares with a $610 price target.
05/14/19
BTIG
05/14/19
UPGRADE
Target $3
BTIG
Buy
TransEnterix upgraded to Buy from Neutral at BTIG
BTIG analyst Sean Lavin upgraded TransEnterix (TRXC) to Buy from Neutral with a $3 price target. The 40% pullback in the shares following the Q1 miss is overdone, Lavin tells investors in a research note. Individual issues at certain hospitals drove the shortfall, and there is a chance that next quarter and beyond could be better, says the analyst. He believes that while Intuitive Surgical (ISRG) using leasing to gain customers adds to TransEnterix's near-term risk, the shares offer more upside potential than downside risk at current prices.
04/22/19
CANT
04/22/19
NO CHANGE
Target $620
CANT
Overweight
Intuitive Surgical weakness on Q1 would be unwarranted, says Cantor Fitzgerald
Cantor Fitzgerald analyst Craig Bijou thinks any potential weakness in shares of Intuitive Surgical today would be unwarranted, given the momentum of the company's underlying business. The slight revenue miss in Q1 was driven by a higher proportion of system placements via lease, which lowers upfront revenue but provides a more stable recurring revenue going forward, Bijou tells investors in a research note. While the analyst expects the stock to see pressure today, he thinks investors should focus on the "impressive underlying business metrics that appear as strong as ever." Bijou reiterates an Overweight rating on Intuitive Surgical with a $620 price target.
AA Alcoa
$23.42

0.27 (1.17%)

07/18/19
JEFF
07/18/19
DOWNGRADE
Target $23
JEFF
Hold
Alcoa downgraded to Hold from Buy at Jefferies
Jefferies analyst Christopher LaFemina downgraded Alcoa to Hold from Buy and lowered his price target for the shares to $23 from $29.
07/11/19
07/11/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Parker-Hannifin (PH) downgraded to Market Perform from Outperform at Wells Fargo with analyst Andrew Casey saying future potential appears to be increasingly complicated by ongoing end market growth deceleration in the U.S. 2. Allstate (ALL) downgraded to Underperform from Neutral at Credit Suisse with analyst Michael Zaremski calling it the insurer most levered to homeowners' insurance at a time when record levels of precipitation in the U.S. raises the probability of worse than expected "non-catastrophe" claims volumes in the homeowners' line of business. 3. Alcoa (AA) downgraded to Hold from Buy at Deutsche Bank with analyst Chris Terry saying he previously thought Alcoa's legacy liabilities from pension and debt would reduce, the aluminum chain pricing will improve, and that its free cash flow would increase. However, he no longer sees this playing out in the near term. 4. Werner (WERN) downgraded to Underperform from Neutral at Credit Suisse with analyst Allison Landry saying that with a weakening demand backdrop, contract TL rates that are turning negative, and anecdotal evidence that suggests capacity remains relatively loose, she sees fairly meaningful risk to the second half of 2019 and 2020 EPS for the asset based truckers. 5. Hamilton Lane (HLNE) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Robert Lee citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/11/19
DBAB
07/11/19
DOWNGRADE
Target $23
DBAB
Hold
Deutsche Bank downgrades Alcoa to Hold, cuts price target to $23
Deutsche Bank analyst Chris Terry last night downgraded Alcoa to Hold from Buy and lowered his price target for the shares to $23 from $35. The analyst previously thought Alcoa's legacy liabilities from pension and debt would reduce, the aluminum chain pricing will improve, and that its free cash flow would increase. However, he no longer sees this playing out in the near term.
07/18/19
JEFF
07/18/19
DOWNGRADE
Target $23
JEFF
Hold
Jefferies downgrades Alcoa to Hold, cuts price target to $23 from $29
Jefferies analyst Christopher LaFemina downgraded Alcoa to Hold from Buy and lowered his price target for the shares to $23 from $29. The stock in after-hours trading is down 21c to $23.20. The shares are inexpensive on some metrics following yesterday's Q2 results, but that alone is not reason enough to buy them, LaFemina tells investors in a research note after Thursday's closing bell. The company is not generating free cash flow, not returning large-scale capital to shareholders, and is leveraged to commodities with relatively poor fundamentals, contends the analyst. As such, he sees a lack of positive catalysts for the shares.

TODAY'S FREE FLY STORIES

NOVA

Sunnova Energy

$11.13

0.089 (0.81%)

21:22
08/19/19
08/19
21:22
08/19/19
21:22
Initiation
Sunnova Energy initiated at KeyBanc »

Sunnova Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

SPY

SPDR S&P 500 ETF Trust

$292.31

3.52 (1.22%)

, SPX

S&P 500

$0.00

(0.00%)

20:54
08/19/19
08/19
20:54
08/19/19
20:54
Periodicals
Trump administration considering steps on economy if conditions worsen, NYT says »

White House officials…

SPY

SPDR S&P 500 ETF Trust

$292.31

3.52 (1.22%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSS

Kohl's

$48.20

2.69 (5.91%)

, TJX

TJX

$51.55

0.13 (0.25%)

20:25
08/19/19
08/19
20:25
08/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KSS

Kohl's

$48.20

2.69 (5.91%)

TJX

TJX

$51.55

0.13 (0.25%)

MDT

Medtronic

$104.15

1.42 (1.38%)

HD

Home Depot

$207.98

4.335 (2.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 20

    Aug

  • 20

    Aug

  • 20

    Aug

  • 04

    Sep

  • 09

    Sep

BHP

BHP Group

$49.12

0.31 (0.64%)

19:32
08/19/19
08/19
19:32
08/19/19
19:32
Hot Stocks
BHP Group sees China and global economic growth slowing »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

BHP

BHP Group

$49.12

0.31 (0.64%)

19:25
08/19/19
08/19
19:25
08/19/19
19:25
Earnings
BHP Group reports FY19 Net profit up 124% at $8.31B »

Reports FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

AAPL

Apple

$210.32

3.88 (1.88%)

19:09
08/19/19
08/19
19:09
08/19/19
19:09
Periodicals
Apple aims for November launch of Apple+, Bloomberg reports »

Apple is targeting a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

$195.19

2.005 (1.04%)

19:04
08/19/19
08/19
19:04
08/19/19
19:04
Hot Stocks
Accenture acquires Parker Fitzgerald, terms not disclosed »

Accenture has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Oct

BIDU

Baidu

$104.28

7.63 (7.89%)

, NBRV

Nabriva Therapeutics

$2.21

-0.06 (-2.64%)

18:47
08/19/19
08/19
18:47
08/19/19
18:47
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Baidu…

BIDU

Baidu

$104.28

7.63 (7.89%)

NBRV

Nabriva Therapeutics

$2.21

-0.06 (-2.64%)

MRNA

Moderna

$13.41

0.235 (1.78%)

VSLR

Vivint Solar

$8.30

0.3 (3.75%)

FN

Fabrinet

$56.40

0.77 (1.38%)

IQ

iQIYI

$18.10

1.02 (5.97%)

MRUS

Merus

$18.46

1.75 (10.47%)

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 20

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 04

    Sep

  • 09

    Sep

  • 12

    Sep

ET

Energy Transfer LP

$13.77

0.3 (2.23%)

18:40
08/19/19
08/19
18:40
08/19/19
18:40
Periodicals
Energy Transfer LP performing maintenance on WTG pipeline, Reuters says »

A spokeswoman for Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$210.32

3.88 (1.88%)

, SNE

Sony

$55.71

-0.01 (-0.02%)

18:20
08/19/19
08/19
18:20
08/19/19
18:20
Periodicals
Apple allocates over $6B for original TV shows and movies, FT says »

Apple (AAPL) has budgeted…

AAPL

Apple

$210.32

3.88 (1.88%)

SNE

Sony

$55.71

-0.01 (-0.02%)

NFLX

Netflix

$309.40

6.66 (2.20%)

DIS

Disney

$135.33

0.14 (0.10%)

T

AT&T

$35.40

0.42 (1.20%)

CBS

CBS

$44.21

0.38 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 05

    Sep

  • 23

    Sep

  • 23

    Oct

LGIH

LGI Homes

$78.56

3.36 (4.47%)

18:01
08/19/19
08/19
18:01
08/19/19
18:01
Hot Stocks
LGI Homes opens two new communities in greater Seattle market »

LGI Homes announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,816.29

24.47 (1.37%)

18:01
08/19/19
08/19
18:01
08/19/19
18:01
Hot Stocks
Amazon.com to expand in Utah with new new fulfillment center »

Amazon.com announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

WMT

Walmart

$113.76

0.77 (0.68%)

18:00
08/19/19
08/19
18:00
08/19/19
18:00
Hot Stocks
Walmart to pay $100,000 to settle EEOC disability discrimination suit »

Wal-Mart Stores East, LP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

X

U.S. Steel

$12.42

1.13 (10.01%)

17:58
08/19/19
08/19
17:58
08/19/19
17:58
Periodicals
U.S. Steel to lay off hundreds of workers at Great Lakes plant, Reuters says »

U.S. Steel plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

17:53
08/19/19
08/19
17:53
08/19/19
17:53
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta falls over 4% or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

17:52
08/19/19
08/19
17:52
08/19/19
17:52
Hot Stocks
FDA's CRL to Sarepta's golodirsen citing risk of infection, renal toxicity »

Sarepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

BSX

Boston Scientific

$42.74

0.59 (1.40%)

17:41
08/19/19
08/19
17:41
08/19/19
17:41
Hot Stocks
Boston Scientific's ImageReady MRI labeling receives FDA approval »

Boston Scientific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 09

    Sep

  • 13

    Nov

AMZN

Amazon.com

$1,816.29

24.47 (1.37%)

, GOOG

Alphabet

$1,198.01

21.07 (1.79%)

17:35
08/19/19
08/19
17:35
08/19/19
17:35
Periodicals
State AGs to proceed with antitrust investigation of big tech, WSJ reports »

A group of state…

AMZN

Amazon.com

$1,816.29

24.47 (1.37%)

GOOG

Alphabet

$1,198.01

21.07 (1.79%)

GOOGL

Alphabet Class A

$1,199.94

21.25 (1.80%)

FB

Facebook

$186.22

2.8 (1.53%)

MSFT

Microsoft

$138.43

2.3 (1.69%)

AAPL

Apple

$210.32

3.88 (1.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

FB

Facebook

$186.22

2.8 (1.53%)

17:31
08/19/19
08/19
17:31
08/19/19
17:31
Periodicals
FTC head says breaking up Facebook could be complicated, FT reports »

Federal Trade Commission…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

MPW

Medical Properties Trust

$18.28

0.13 (0.72%)

17:28
08/19/19
08/19
17:28
08/19/19
17:28
Hot Stocks
Medical Properties Trust COO sells 100K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

WMT

Walmart

$113.76

0.77 (0.68%)

17:17
08/19/19
08/19
17:17
08/19/19
17:17
Periodicals
Walmart's U.S. Chief Marketing Officer Barbara Messing is leaving, AdAge says »

Walmart U.S. Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

MAXR

Maxar Technologies

$6.49

0.185 (2.93%)

17:12
08/19/19
08/19
17:12
08/19/19
17:12
Hot Stocks
Maxar Technologies' MDA awarded Canadian Space Agency contract »

MDA, a Maxar company, has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCI

Rogers Communications

$51.30

0.21 (0.41%)

17:06
08/19/19
08/19
17:06
08/19/19
17:06
Hot Stocks
Rogers 'disappointed' by CRTC decision on broadband wholesale rates »

Rogers Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IQ

iQIYI

$18.10

1.02 (5.97%)

17:05
08/19/19
08/19
17:05
08/19/19
17:05
Hot Stocks
Breaking Hot Stocks news story on iQIYI »

iQIYI down over 6% or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

IQ

iQIYI

$18.10

1.02 (5.97%)

17:03
08/19/19
08/19
17:03
08/19/19
17:03
Hot Stocks
iQIYI reports Q2 total subscribing members 100.5M, up 50% from last year »

iQIYI's number of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.